Resolutions from AQILION AB (publ) Annual General Meeting 2024
Helsingborg, June 10, 2024 – AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance with the proposals presented. For more detailed information on the content of the resolutions, please see the full notice to the Annual General Meeting, which is available on Aqilion's website, www.aqilion.com
Adoption of income statements and balance sheets
The Annual General Meeting approved the income statement and balance sheet included in the annual report for the business year 2023. The Annual General Meeting decided that the entire amount at the disposal of the Annual General Meeting should be balanced in a new account. The Annual General Meeting granted the Board members and the CEO discharge from liability for the 2023 financial year.
Resolution on dividend
The Annual General Meeting decided that no dividend shall be paid for the financial year 2023.
Determination of the number of Board members and election of the Board
The Annual General Meeting decided that the Board should consist of six regular members with no deputies.
Roland Andersson (re-election), Bertil Lindmark (re-election), Martin Olovsson (re-election), Gunilla Savring (re-election), Kristina Masson (re-election) and Anders Kronborg (re-election) were elected Board members for the period until the next Annual General Meeting. Bertil Lindmark was elected Chairman of the Board.
Determination of renumeration for the Board of Directors and the Auditor
The Annual General Meeting decided that renumeration until the end of the next Annual General Meeting shall be SEK 210,000 to the Chairman of the Board, and SEK 100,000 per Board member who is not employed by the Company, and that renumeration to the Auditors shall be paid on approved account.
Election of Auditors
Mazars AB Helsingborg with Chief auditor Andreas Brodström was re-elected as auditors for the time until the next Annual General Meeting.
Determining the principles for the appointment of the Nomination Committee and it's mission
The Annual General Meeting decided according to the Nomination Committee's proposal. The Comination Committee for the AQILION AB 2023 Annual General Meeting consisted of Christian Ewe, Linus Wiebe and Katarina Berggren. The decision on instructions for the Nomination Committee shall apply until the Annual General Meeting decides otherwise.
Establishing guidelines for remuneration to senior executives
According to the Board's proposal, the Annual General Meeting resolves on the following guidelines for remuneration to senior executives to apply until the end of the Annual General Meeting in 2028.
Decision on authorization for the Board to decide on the issue of shares, convertibles and/or warrants
The Annual General Meeting decided to authorize the Board to, on one or more occasions during the period until the next Annual General Meeting, with or without deviating from the shareholders' pre-emptive rights, decide on the issue of shares, convertibles and/or warrants. An issue may be made against cash payment and/or with a provision for in-kind or set-off or otherwise with conditions according to the Swedish Companies Act. By resolutions based on the authorization, the number of shares may be increased by a
number corresponding to a maximum of thirty (30) percent of the outstanding shares in the
company at the time when the Board of Directors first exercises the authorization.
Resolution to proposed changes in the articles of association
The Annual General Meeting decided according to the board's proposal on changes to the articles of association.
For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com
About Aqilion
Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.
We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.
The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes it’s development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.
AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com
Tags: